Loading…
MetaVia Inc. is projected to decline to $1.44 by 2027, a -3% move from its current price of $1.48. MTVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.41 | $1.48 | $1.55 | -0.06% |
| Aug 6 | $1.39 | $1.48 | $1.58 | -0.12% |
| Aug 7 | $1.37 | $1.48 | $1.60 | -0.17% |
| Aug 8 | $1.35 | $1.48 | $1.62 | -0.23% |
| Aug 9 | $1.33 | $1.48 | $1.63 | -0.29% |
| Aug 10 | $1.32 | $1.47 | $1.65 | -0.35% |
| Aug 11 | $1.31 | $1.47 | $1.66 | -0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.31 | $1.47 | $1.66 | -0.41% |
| Week 2 | $1.24 | $1.47 | $1.74 | -0.81% |
| Week 3 | $1.19 | $1.46 | $1.80 | -1.22% |
| Week 4 | $1.15 | $1.46 | $1.85 | -1.62% |
| Week 5 | $1.11 | $1.45 | $1.89 | -2.02% |
| Week 6 | $1.08 | $1.44 | $1.93 | -2.42% |
| Week 7 | $1.05 | $1.44 | $1.97 | -2.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MetaVia Inc. is a healthcare company that operates in the clinical-stage biotechnology space and focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy, in Phase 2a for metabolic dysfunction-associated steatohepatitis, and it has completed Phase 1 for type 2 diabetes mellitus.
It also develops DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, in Phase 1 for obesity.
Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for moderate COVID-19; NB-01 for painful diabetic neuropathy; NB-02 for cognitive impairment; and Gemcabene for dyslipidemia. The company has a license agreement with Pfizer Inc. for Gemcabene, and Dong-A ST is the sole manufacturer for the production of DA-1241 and DA-1726.
MetaVia was formerly NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. The company is headquartered in Cambridge, Massachusetts.
MetaVia Inc. trades as MTVA in the Healthcare space and currently reports a price of $1.45 with a market capitalization of $7.49M and a rank of 4989. The near-term price trajectory is mixed, with neutral to bearish signals indicated by the 30-day technical picture.
The forecast includes a wide range of potential outcomes across years, showing gradual upside over the long run, including a high-max scenario by 2050. These are estimates, not guarantees.
A major floor 34.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.1% below — buyers have tended to step in here.
The nearest ceiling, 34.5% above — a clean break opens room to run.
A major ceiling 160.1% above — clearing it would confirm fresh momentum.
Key MTVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MTVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.44 | Buy | $1.45 | Buy |
| MA 10 | $1.50 | Sell | $1.50 | Sell |
| MA 20 | $1.62 | Sell | $1.58 | Sell |
| MA 50 | $1.95 | Sell | $1.72 | Sell |
| MA 100 | $1.67 | Sell | $2.21 | Sell |
| MA 200 | $4.11 | Sell | $4.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.54 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -90.60 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -23.24 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 10.08 | Buy |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.41 | Buy |
| ADX (14) | 17.22 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bearish. RSI14 is 40, with the price sitting relative to key moving averages: SMA50 at $1.94 and SMA200 at $4.31. The stock sits near support at $1.43 and faces resistance at $1.99. The 30-day range spans $1.04 to $2.03, highlighting notable near-term volatility with annualized volatility around 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.97 | $1.48 | $2.01 | 0% | Neutral | |
| $1.08 | $1.44 | $2.07 | -3% | Neutral | |
| $1.39 | $1.94 | $2.95 | +31% | Bullish | |
| $1.44 | $2.11 | $3.34 | +42% | Bullish | |
| $1.24 | $1.89 | $3.10 | +27% | Bullish | |
| $1.32 | $2.07 | $3.51 | +40% | Bullish | |
| $1.15 | $1.87 | $3.26 | +26% | Bullish | |
| $0.9787 | $1.64 | $2.93 | +11% | Neutral | |
| $1.20 | $2.07 | $3.79 | +40% | Bullish | |
| $1.42 | $2.52 | $4.71 | +70% | Bullish | |
| $1.20 | $2.47 | $5.02 | +67% | Bullish | |
| $2.49 | $5.54 | $12.72 | +274% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.97 | $1.48 | $1.87 | +0.00% |
| September 2026 | $1.22 | $1.46 | $1.83 | -1.09% |
| October 2026 | $1.15 | $1.40 | $1.79 | -4.14% |
| November 2026 | $1.21 | $1.48 | $1.92 | +5.82% |
| December 2026 | $1.24 | $1.54 | $2.01 | +3.75% |
Click any year to see its month-by-month MTVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MTVA could reach as high as $2.01, with a base case around $1.48 and support toward $0.97 — roughly 0% from $1.48. A consolidation phase looks the most probable path here.
Expect MTVA to range from $1.08 to $2.07 through 2027. The $1.44 average target implies a -3% move from current prices. That is -3% versus the projected 2026 average. Price action looks broadly range-bound.
The MTVA price prediction for 2028 points to an average of $1.94 (low $1.39, high $2.95) — a potential gain of +31% on today's $1.48. Buyers look set to stay in control over this stretch.
In 2029, MTVA is projected to trade between $1.44 and $3.34, averaging $2.11 — a potential gain of +42% from today's $1.48. That is up +8% on the projected 2028 average. Momentum favours further upside here.
MetaVia Inc.'s 2030 outlook centres on $1.89, within a $1.24 to $3.10 range. That is -11% versus the projected 2029 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MTVA could reach as high as $3.51, with a base case around $2.07 and support toward $1.32 — roughly +40% from $1.48. Momentum favours further upside here.
Expect MTVA to range from $1.15 to $3.26 through 2032. The $1.87 average target implies a +26% move from current prices. That is -10% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The MTVA price prediction for 2033 points to an average of $1.64 (low $0.9787, high $2.93) — a potential gain of +11% on today's $1.48. Price action looks broadly range-bound.
In 2034, MTVA is projected to trade between $1.20 and $3.79, averaging $2.07 — a potential gain of +40% from today's $1.48. That is up +26% on the projected 2033 average. Buyers look set to stay in control over this stretch.
MetaVia Inc.'s 2035 outlook centres on $2.52, within a $1.42 to $4.71 range. That is up +22% on the projected 2034 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2040, MTVA could reach as high as $5.02, with a base case around $2.47 and support toward $1.20 — roughly +67% from $1.48. Buyers look set to stay in control over this stretch.
Expect MTVA to range from $2.49 to $12.72 through 2050. The $5.54 average target implies a +274% move from current prices. That is up +124% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MTVA today (≈ 675.675676 MTVA) could be worth
$3,741.05
+$2,741.05 (+274%) by 2050 · US Dollar
Based on the average projected MTVA price of $5.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MTVAwould be worth at today's price.
$1,000 invested in MTVA on Jul 31, 2025 (≈ 150.262955 MTVA) would be worth
$222.39
-$777.61 (-77.8%) today · 0.22× · US Dollar
Based on a MTVA entry price of $6.66 vs. today's $1.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.48 | $1,000 | -0.0% |
| 1 month ago | $1.45 | $1,020.69 | +2.1% |
| 3 months ago | $1.44 | $1,027.78 | +2.8% |
| 6 months ago | $2.31 | $640.69 | -35.9% |
| 1 year ago | $6.66 | $222.39 | -77.8% |
| All time (5.0y) ago | $9,741.6 | $0.15 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MTVA forecast.
Our base-case forecast reaches $3.00 around 2050.
Implied market cap at $3.00: $15.49M
Multi-year forecasts span 2026 through 2050. The 2026–2027 outlook is neutral, with 2026 min $0.97, avg $1.45, max $2.01 and 2027 min $1.03, avg $1.41, max $2.07, yielding ROI values of 0 and -3 respectively. The 2028–2035 window turns bullish, with 2028 min $1.37, avg $1.98, max $3.10 (ROI 36.6%), 2029 min $1.40, avg $2.12, max $3.48 (ROI 46.5%), 2030 min $1.19, avg $1.88, max $3.21 (ROI 29.6%), 2031 min $1.28, avg $2.11, max $3.72 (ROI 45.5%), 2032 min $1.06, avg $1.82, max $3.31 (ROI 25.7%), and 2033 min $0.8762, avg $1.56, max $2.92 (ROI 7.8%).
The forecast remains bullish through 2034–2035 (2034 min $1.14, avg $2.11, max $4.03; ROI 45.3% and 2035 min $1.32, avg $2.54, max $4.97; ROI 75.3%). Long-horizon upside accelerates, with 2040 min $1.10, avg $2.45, max $5.26 (ROI 69%), and 2050 min $2.51, avg $5.57, max $12.82 (ROI 284.4%).
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.88 with a range from $1.19 to $3.21 and an estimated ROI of 29.6%, within a bullish outlook.
Forecasts indicate neutral sentiment in 2026 and 2027 followed by bullish sentiment from 2028 onward, with an eventual high upside by 2050 (average $5.57, max $12.82) and a 284.4% ROI in 2050. These are estimates, not guarantees.
Yes. The 2050 forecast lists a max of $12.82, which exceeds $10, though actual results can vary and are not guaranteed.
$7.49M.
MetaVia Inc. Community Discussion
0Share your MetaVia Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.